US jury ordered Johnson & Johnson to pay 55 million dollar for causing cancer

May 5, 2016 10:07 IST

J&JUS jury of St Louise on 2 May 2016 ordered Johnson & Johnson (J&J) to pay 55 million US dollars to a woman, Gloria Ristesund, who claimed that company’s talcum powder caused her ovarian cancer. It is the second such judgment against J&J in three months.

The verdict came after a three-week trial in Missouri state court. The Judges in their verdict awarded 5 million US dollars in compensatory damages and 50 million US dollars in punitive damages.

Ristesund, in her suit claimed that she used J&J's talc-based powder products which include the Baby Powder and Shower to Shower Powder on her genitals for decades. And, she was diagnosed with ovarian cancer and had to undergo a hysterectomy and related surgeries.

The verdict followed a 72 million US dollar jury award to the family of Jacqueline Fox, who died from ovarian cancer after years of using talc powder for feminine hygiene from the same court in February 2016.

The only other case to be tried involving talc powder and ovarian cancer resulted in a mixed verdict in South Dakota federal court in 2013. While those jurors found J&J was negligent, they awarded no damages to the plaintiff, whose cancer was in remission at the time of the trial.

Now get latest Current Affairs on mobile, Download # 1 Current Affairs App

Is this article important for exams ? Yes8 People Agreed
Read more Current Affairs on: US jury , Johnson & Johnson , J&J fined , cancer , talc

DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.

Latest Videos

Register to get FREE updates

    All Fields Mandatory
  • (Ex:9123456789)
  • Please Select Your Interest
  • Please specify

  • ajax-loader
  • A verifcation code has been sent to
    your mobile number

    Please enter the verification code below

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK